Outcomes in COVID-19 olokizumab studies

All studies   Mortality   Serious outcomes   RCTs   RCT mortality   All outcomes  
0 0.5 1 1.5+ All studies -50% 1 248 Improvement, Studies, Patients Relative Risk Mortality -50% 1 248 RCTs -50% 1 248 Late -50% 1 248 Olokizumab for COVID-19 c19early.org December 2025 Favorsolokizumab Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Samsonov (DB RCT) -50% 1.50 [0.55-4.09] death 9/124 6/124 Improvement, RR [CI] Treatment Control RESET Samsonov (RCT) unknown, >2 years late 198 (total) Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.44 Late treatment -50% 1.50 [0.55-4.09] 9/124 6/124 50% higher risk All studies -50% 1.50 [0.55-4.09] 9/124 6/124 50% higher risk 1 olokizumab COVID-19 study (+1 unreported RCT) c19early.org December 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.44 Effect extraction pre-specified(most serious outcome) Favors olokizumab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Samsonov (DB RCT) -50% 1.50 [0.55-4.09] 9/124 6/124 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.44 Late treatment -50% 1.50 [0.55-4.09] 9/124 6/124 50% higher risk All studies -50% 1.50 [0.55-4.09] 9/124 6/124 50% higher risk 1 olokizumab COVID-19 mortality result c19early.org December 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.44 Favors olokizumab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Samsonov (DB RCT) -50% 1.50 [0.55-4.09] death 9/124 6/124 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.44 Late treatment -50% 1.50 [0.55-4.09] 9/124 6/124 50% higher risk All studies -50% 1.50 [0.55-4.09] 9/124 6/124 50% higher risk 1 olokizumab COVID-19 serious outcome c19early.org December 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.44 Effect extraction pre-specified(most serious outcome) Favors olokizumab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Samsonov (DB RCT) -50% 1.50 [0.55-4.09] death 9/124 6/124 Improvement, RR [CI] Treatment Control RESET Samsonov (RCT) unknown, >2 years late 198 (total) Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.44 Late treatment -50% 1.50 [0.55-4.09] 9/124 6/124 50% higher risk All studies -50% 1.50 [0.55-4.09] 9/124 6/124 50% higher risk 1 olokizumab COVID-19 Randomized Controlled Trial c19early.org December 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.44 Effect extraction pre-specified(most serious outcome) Favors olokizumab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Samsonov (DB RCT) -50% 1.50 [0.55-4.09] 9/124 6/124 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.44 Late treatment -50% 1.50 [0.55-4.09] 9/124 6/124 50% higher risk All studies -50% 1.50 [0.55-4.09] 9/124 6/124 50% higher risk 1 olokizumab COVID-19 RCT mortality result c19early.org December 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.44 Favors olokizumab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Samsonov (DB RCT) -50% 1.50 [0.55-4.09] death 9/124 6/124 Improvement, RR [CI] Treatment Control Samsonov (DB RCT) 30% 0.70 [0.42-1.15] no improv. 21/124 30/124 Samsonov (DB RCT) 30% 0.70 [0.45-1.09] no improv. 26/124 37/124 Olokizumab COVID-19 outcomes c19early.org December 2025 Favors olokizumab Favors control